Leading the next revolution for tackling solid tumors

At Avstera, our primary focus is to address the significant unmet need of advanced cancer patients who have limited or no treatment options. These include patients who fail to respond to existing therapies, or end up developing resistance to immunotherapy. With our proprietary pipeline of oncology programs, including an ultra-specific HDAC6i (AVS100), autologous HDAC6i activated macrophage-based cell therapy (AVS200), and mRNA cancer vaccine encoding TEM1 (AVS300), we will offer revolutionary solutions targeting solid tumors and addressing a significant unmet need for patients across all tumor types.